Funding agencies: This trial was funded by Noscira SA.
A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy
Article first published online: 14 FEB 2014
© 2014 International Parkinson and Movement Disorder Society
Volume 29, Issue 4, pages 470–478, April 2014
How to Cite
Tolosa, E., Litvan, I., Höglinger, G. U., Burn, D., Lees, A., Andrés, M. V., Gómez-Carrillo, B., León, T., del Ser, T., for the TAUROS Investigators (2014), A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov. Disord., 29: 470–478. doi: 10.1002/mds.25824
Relevant conflicts of interest/financial disclosures: Nothing to report.
Full financial disclosures and author roles may be found in the online version of this article.
Members of the TAUROS Investigators are listed in the Appendix.
- Issue published online: 3 APR 2014
- Article first published online: 14 FEB 2014
- Manuscript Accepted: 20 DEC 2013
- Manuscript Revised: 17 DEC 2013
- Manuscript Received: 1 OCT 2013
Additional Supporting Information may be found in the online version of this article.
|mds25824-sup-0001-supptables.doc||76K||Supporting Information Tables|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.